Lv51
1510 积分 2024-05-21 加入
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
21天前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
21天前
已完结
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
21天前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
21天前
已完结
Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
21天前
已完结
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
1个月前
已完结
Immunogenicity of the pentavalent rotavirus vaccine in African infants
3个月前
已完结
Immunogenicity of pentavalent rotavirus vaccine in Chinese infants
3个月前
已完结
五价轮状病毒疫苗在中国婴儿中的免疫原性
3个月前
已完结
五价轮状病毒疫苗在中国婴儿中的免疫原性
3个月前
已关闭
皖公网安备34019202002308
